GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Liabilities-to-Assets

MindBio Therapeutics (XCNQ:MBIO) Liabilities-to-Assets : 19.03 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. MindBio Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was C$5.27 Mil. MindBio Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was C$0.28 Mil. Therefore, MindBio Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 19.03.


MindBio Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for MindBio Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Liabilities-to-Assets Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Liabilities-to-Assets
1.99 3.62 9.06

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.05 9.06 21.55 39.23 19.03

Competitive Comparison of MindBio Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, MindBio Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindBio Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Liabilities-to-Assets falls into.



MindBio Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

MindBio Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Liabilities-to-Assets (A: Jun. 2023 )=Total Liabilities/Total Assets
=5.433/0.6
=9.06

MindBio Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=5.272/0.277
=19.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MindBio Therapeutics  (XCNQ:MBIO) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


MindBio Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

By Stock market mentor Stock market mentor 01-17-2023